Trials / Completed

CompletedNCT03276013

Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer

Phase II Trial of Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 48 (actual)

Sponsor: Vall d'Hebron Institute of Oncology · Academic / Other
Sex: Female
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.

Conditions

Endometrial Neoplasms

Interventions

Type	Name	Description
DRUG	Pembrolizumab	pembrolizumab in combination with doxorubicin

Timeline

Start date: 2018-05-30
Primary completion: 2020-04-30
Completion: 2021-08-26
First posted: 2017-09-08
Last updated: 2021-10-05

Locations

7 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT03276013. Inclusion in this directory is not an endorsement.